Using a Computerized Drug Prescription Screening System to Trace Drug Interactions in an Outpatient Setting

Abstract

Spanish

French

BACKGROUND:

Drug—drug interactions are one of the main causes of adverse effects. These events have been studied most often in hospital settings; however, investigations on prescribing based on community practice have shown a high prevalence rate of potential drug interactions.

OBJECTIVE:

To develop a computerized system able to trace drug interactions quickly through the identification of clinicians issuing potentially unsafe prescriptions.

METHODS:

We retrospectively evaluated hazardous concomitant prescriptions of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and azole antifungals, which were invoiced through 9 months of 2001 within an outpatient setting. The study was conducted in Badajoz, a southern Spanish province, and was divided in three 3–month periods according to the release of 2 warning notes on this drug combination by the Spanish Drug Agency. Prescriptions written during this period were optically scanned each month, and the resulting information, including data from patients, physicians, and drugs involved, was converted to a database and searched for potentially unsafe coprescriptions.

RESULTS:

A total of 8 342 711 prescriptions were invoiced in the period of study, 174 of which were for a statin—azole combination. The number of these prescriptions remained fairly constant during periods I and II (63 and 71, respectively), decreasing to 40 in period III. Some clinicians (12.6%) repeatedly prescribed a hazardous drug combination at some point in this study, whereas 18 of 171 patients who received the hazardous coprescription at any time did so repeatedly within a given period. The impact of drug alerts was remarkably deeper in urban rather than rural care centers.

CONCLUSIONS:

The computerized drug prescription handling system described here is able to readily identify physicians and patients who issue/consume hazardous drug combinations, thus allowing both the possibility of individually informing the healthcare professionals involved and early detection of adverse effects.

Keywords

azole antifungals computerized prescription handling drug interaction rhabdomyolysis statins

Get full access to this article

View all access options for this article.

References

Hamilton

Briceland

Andritz

MH.

Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998;18:1112–20.

Lazarou

Pomeranz

Corey

PN.

Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200–5.

Hallas

Harvald

Gram

Grodum

Brosen

Haghfelt

Drug related hospital admissions: The role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990;228:83–90.

Colt

, Shapiro AP Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc 1989;37:323–6.

Chan

Nicklason

Vial

JH.

Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001;31:199–205.

McDonnell

Jacobs

. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331–6. DOI 10.1345/aph.1A333.

Tamblyn

Huang

Perreault

Jacques

Roy

Hanley

The medical office of the 21st century (MOXXI): Effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ 2003;169:549–56.

Hanlon

Schmader

Ruby

Weinberger

Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001;49:200–9.

Heerey

Barry

Ryan

Kelly

The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000;169:176–9.

10.

Bates

Pappius

Kuperman

Sittig

Burstin

Fairchild

Using information systems to measure and improve quality. Int J Med Inf 1999;53:115–24.

11.

Bates

Teich

Lee

Seger

Kuperman

Ma'Luf

The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999;6:313–21.

12.

Leape

Brennan

Laird

Lawthers

Localio

Barnes

The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377–84.

13.

Bates

Cullen

Laird

Petersen

Small

Servi

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29–34.

14.

Rosholm

Bjerrum

Hallas

Worm

Gram

LF.

Polypharmacy and the risk of drug—drug interactions among Danish elderly. A prescription database study. Dan Med Bull 1998;45:210–3.

15.

Seymour

Routledge

PA.

Important drug-drug interactions in the elderly. Drugs Aging 1998;12:485–94.

16.

Halkin

Katzir

Kurman

Jan

Malkin

BB.

Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001;69:260–5.

17.

Bottorff

“Fire and forget?” Pharmacological considerations in coronary care. Atherosclerosis 1999;147(suppl 1):S23–30.

18.

Jacobsen

Kirchner

Hallensleben

Mancinelli

Deters

Hackbarth

Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173–9.

19.

Lilja

Kivisto

Neuvonen

PJ.

Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477–83.

20.

Malinowski

JM.

Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998;55:2253–67.

21.

Bourrie

Meunier

Berger

Fabre

Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321–32.

22.

Gibbs

Kunze

Howald

Thummel

KE.

Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999;27:596–9.

23.

Back

Tjia

JF.

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624–6.

24.

Shaukat

Benekli

Vladutiu

Slack

Wetzler

Baer

. Simvastatin—fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032–5. DOI 10.1345/aph.1C467.

25.

Vlahakos

Manginas

Chilidou

Zamanika

Alivizatos

PA.

Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002;73:1962–4.

26.

Omar

Wilson

JP.

FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288–95. DOI 10.1345/aph.1A289.

27.

Omar

Wilson

Cox

TS.

Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096–107. DOI 10.1345/aph.10228.

28.

Guedon-Moreau

Ducrocq

Duc

Quieureux

L'Hote

Deligne

Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: Analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003;59:689–95.

29.

Martin

Hall

Gardner

Prescribing for patients aged 65 years and over in New Zealand general practice. N Z Med J 2002;115:U221.

30.

Magnus

Rodgers

Avery

AJ.

GPs' views on computerized drug interaction alerts: Questionnaire survey. J Clin Pharm Ther 2002;27:377–82.

31.

Glassman

Simon

Belperio

Lanto

Improving recognition of drug interactions: Benefits and barriers to using automated drug alerts. Med Care 2002;40:1161–71.

32.

Isaksen

Jonassen

Malone

Billups

Carter

Sintek

CD.

Estimating risk factors for patients with potential drug-related problems using electronic pharmacy data. IMPROVE investigators. Ann Pharmacother 1999;33:406–12. DOI 10.1345/aph.18268.

33.

Farmer

JA.

Learning from the cerivastatin experience. Lancet 2001;358:1383–5.

34.

Garcia-Valdecasas-Campelo

Gonzalez-Reimers

Lopez-Lirola

Rodriguez-Rodriguez

Santolaria-Fernandez

Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001;161:893.

35.

Hamilton-Craig

Statin-associated myopathy. Med J Aust 2001;175:486–9.